This bill would ban direct-to-consumer advertising by drug manufacturers for certain prescription drugs. It adds a new paragraph to section 502 of the Federal Food, Drug, and Cosmetic Act covering drugs approved under section 505 or licensed under section 351 of the Public Health Service Act and subject to section 503(b)(1). The bill defines "direct-to-consumer advertising" as promotional communications targeting consumers through television, radio, print media, digital platforms, and social media. The amendment would take effect 30 days after enactment and would apply regardless of when a drug was approved or licensed.
If enacted, drug companies could not run ads aimed at consumers for the covered prescription drugs. You would likely stop seeing paid TV, radio, print, online, and social media ads that directly promote those medicines. The bill text does not include details about enforcement, penalties, or specific exceptions.
No publicly available information about budgetary effects, enforcement costs, or fiscal estimates is included in the bill text or metadata provided.
No publicly available information in the bill text or provided metadata describes proponents' stated reasons or arguments.
No publicly available information in the bill text or provided metadata describes opponents' stated reasons or arguments.